Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by lacrimal and salivary gland dysfunction. However, the underlying causes of the pathophysiology of SS disease are relatively unclear. New investigations suggest an association exists between the pathogenesis of SS disease and cytokines. This study purposes to investigate and examine the serum adropin and clusterin serum levels in patients with SS. A total of 88 participants, 44 patients with SS disease (2 men and 42 women) and 44 healthy subjects (2 men and 42 women) were enrolled in the study. Patients’ ages, age of disease onset, gender, SS disease duration, localization, and social history were recorded. Adropin and clusterin levels were determined using the enzyme-linked immunosorbent assay (ELISA) method. The adropin levels were measured as 110.43 ng/L in the SS patient group and 80.06 ng/L in the healthy control group. A remarkable increase was determined in terms of the SS group’s adropin levels compared to the healthy subjects (p=0.047). The clusterin levels were minimally higher in the SS patients compared to the non-SS patients, however, these differences were not statistically significant (p=0.110; 98.41 and 84.59 ng/ml, respectively). The average disease duration in the SS patient group was determined as 46.68 months. Also, the average Eular Sjögren’s syndrome disease activity index (ESSDAI) in the patient with SS was found to be 5.98. Elevated adropin levels were determined in the SS patients. Thus, serum adropin may be a potential biomarker of SS disease. To clarify these findings, further investigations are needed.
Key words: Sjögren's syndrome, adropin, clusterin
|
